Table 5.

Estimated effect of active analgesic treatment on secondary outcome [Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale (MOBID-2) pain intensity] compared with placebo; mixed-model analysis including exploratory subgroup analyses

	N	From baseline to 13 wk			From baseline to 6 wk			From 6 to 13 wk
		C	(95% CI)	P value	C	(95% CI)	P value	C	(95% CI)	P value
Secondary analysis
All patients	147	− 0.19	(− 1.02 to 0.64)	0.652	0.19	(− 0.59 to 0.97)	0.634	− 0.38	(− 1.25 to 0.49)	0.389
Stratified on cognition
MMSE 11–20	44	− 1.01	(− 2.44 to 0.41)	0.162	0.39	(− 0.94 to 1.73)	0.563	− 1.41	(− 2.83 to 0.01)	0.051
MMSE 0–10	87	0.12	(− 1.02 to 1.26)	0.838	0.03	(− 1.05 to 1.11)	0.960	0.09	(− 1.13 to 1.32)	0.884
Stratified on drug type
Paracetamol/placebo tablets	69	− 0.98	(− 2.00 to 0.05)	0.061	0.14	(− 0.83 to 1.10)	0.779	− 1.11	(− 2.16 to −0.06)	0.037
Buprenorphine/placebo TDS	78	0.47	(− 0.77 to 1.71)	0.456	0.21	(− 0.98 to 1.39)	0.733	0.26	(− 1.06 to 1.59)	0.697
Stratified on pain level
MOBID-2 ≥ 3	90	− 0.57	(− 1.77 to 0.62)	0.347	−0.16	(− 1.24 to 0.93)	0.779	− 0.42	(− 1.63 to 0.79)	0.498
MOBID-2 ≥ 3 and paracetamol	38	− 1.36	(− 3.27 to 0.55)	0.164	0.07	(− 1.67 to 1.82)	0.933	− 1.43	(− 3.25 to 0.39)	0.123
MOBID-2 ≥ 3 and buprenorphine	52	0.23	(− 1.32 to 1.77)	0.775	−0.38	(− 1.81 to 1.05)	0.607	0.60	(− 1.04 to 2.25)	0.474

C coefficient for time × treatment interaction, CI confidence interval, CSDD Cornell Scale for Depression in Dementia, MMSE Mini-Mental State Examination, N number of patients with at least one valid assessment, TDS transdermal system. See also the Electronic Supplementary Material 3, which reports all corresponding coefficients for change